Primary hyperaldosteronism

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
2 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
V Various (ATC V) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase III: 1 Phase II/III: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • AstraZeneca AB Commercial
    BAXDROSTAT
    2025-520740-16-00 4 countries 2025 n=49
    Recruiting

Phase II/III

2 trials
  • Assistance Publique Hopitaux De Paris Academic
    GALLIUM (68GA), PENTIXAFOR
    2023-505507-22-00 1 country 2024 n=60
    Ended
  • Radboud universitair medisch centrum Stichting Academic
    GALLIUM (68GA), PENTIXAFOR
    2024-512628-12-00 1 country 2025 n=228
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AstraZeneca AB Commercial 1 Phase III 1
Assistance Publique Hopitaux De Paris Academic 1 Phase II/III 0
Radboud universitair medisch centrum Stichting Academic 1 Phase II/III 1
New trials by year
2024
1
2025
2
← All indication landscapes